Vernalis PLC: Notice of Results for 6 Months Ended 30 June 2013

WINNERSH, UNITED KINGDOM--(Marketwired - July 11, 2013) -

Vernalis PLC (LSE: VER)

 11 July 2013 LSE: VER Notice of Results for the Six Months Ended 30 June 2013 Vernalis plc today announces its half year results for the six months ended 30 June 2013 will be released on Monday, 29 July 2013. The earnings announcement will be distributed at 7:00 am (UK) and will be available to download from www.vernalis.com. Following the results announcement, the Company will host an analyst presentation and concurrent conference call at 9:30 am (UK) on 29 July 2013. The presentation will be held at the offices of Brunswick Group, 16 Lincoln’s Inn Fields, London, WC2A 3ED. Please contact Valerie Mugridge at Brunswick on +44 (0) 207 396 5325 for details. -- ends -- Enquiries: Vernalis Contacts: Ian Garland, Chief Executive Officer +44 (0) 118 938 0015 David Mackney, Chief Financial Officer Nomura Code Securities Limited: +44 (0) 20 7776 1200 Juliet Thompson Jonathan Senior Brunswick Group: +44 (0) 20 7404 5959 Jon Coles Notes to Editors About Vernalis Vernalis is a revenue generating development stage pharmaceutical company with significant expertise in drug development. The Group has one marketed product, frovatriptan for the acute treatment of migraine, an exclusive licensing agreement to develop and commercialise multiple novel products focussed on the US prescription cough cold market as well as seven programmes in its NCE development pipeline. Vernalis has also significant expertise in fragment and structure based drug discovery which it leverages to enter into collaborations with larger pharmaceutical companies. The Company’s technologies, capabilities and products have been endorsed over the last five years by collaborations with leading pharmaceutical companies, including Biogen Idec, Endo, GSK, Genentech, Lundbeck, Menarini, Novartis, Servier and Tris. For further information about Vernalis, please visit www.vernalis.com Vernalis Forward-Looking Statement This news release may contain forward-looking statements that reflect the Company’s current expectations regarding future events including the clinical development and regulatory clearance of the Company’s products, the Company’s ability to find partners for the development and commercialisation of its products, as well as the Company’s future capital raising activities. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors including the success of the Company’s research strategies, the applicability of the discoveries made therein, the successful and timely completion ofclinical studies, the uncertainties related to the regulatory process, the ability of the Company to identify and agree beneficial terms with suitable partners for the commercialisation and/or development of its products, as well as the achievement of expected synergies from such transactions, the acceptance of frovatriptan and other products by consumers and medical professionals, the successful integration of completed mergers and acquisitions and achievement of expected synergies from such transactions, and the ability of the Company to identify and consummate suitable strategic and business combination transactions. This information is provided by RNS The company news service from the London Stock Exchange END